The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells

Lung cancer patients face a dismal prognosis mainly due to the low efficacy of current available treatments. Cisplatin is the first-line chemotherapy treatment for those patients, however, resistance to this drug is a common and yet not fully understood phenomenon. Aiming to shed new light into this...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Matheus Molina, Rocha, Clarissa Ribeiro Reily, Kinker, Gabriela Sarti, Pelegrini, Alessandra Luiza, Menck, Carlos Frederico Martins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881285/
https://www.ncbi.nlm.nih.gov/pubmed/31776385
http://dx.doi.org/10.1038/s41598-019-54065-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881285/
https://www.ncbi.nlm.nih.gov/pubmed/31776385
http://dx.doi.org/10.1038/s41598-019-54065-6

Ejemplares similares